- Fund Type: SICAV
- Objective: Growth
- Asset Class: Equity
- Geographic Focus: Spain
Aledanos de Inversion SICAV SA
+ Add to WatchlistADI:SM
9.44 EUR 0.000.00%As of 10:00:40 ET on 05/22/2013.
Snapshot for Aledanos de Inversion SICAV SA (ADI)
| Year To Date: | +2.69% | 3-Month: | +2.08% | 3-Year: | +3.24% | 52-Week Range: | 8.80 - 9.44 |
|---|---|---|---|---|---|---|---|
| 1-Month: | +1.20% | 1-Year: | +6.46% | 5-Year: | +3.26% | Beta vs IBEX: | 0.37 |
Fund Profile & Information for ADI
Aledanos de Inversion SICAV SA is an open-end investment company incorporated in Spain. The investment company's objective is capital growth. It primarily invests in equity securities.
| Inception Date: | 12-19-2006 | Telephone: | +34.91.781.32.76 |
|---|---|---|---|
| Managers: | - | ||
| Web Site: | www.bbva.es | ||
Fundamentals for ADI
| NAV | (on 2013-05-22) 9.44 |
|---|---|
| Assets (M) | (on 2013-04-04) 2.88 |
| Fund Leveraged | N |
| Minimum Investment | - |
| Minimum Subsequent Investment | - |
Dividends for ADI
No dividends reported
Fees & Expenses for ADI
| Front Load | - |
|---|---|
| Back Load | - |
| Current Mgmt Fee | - |
| Redemption Fee | - |
| 12b1 Fee | - |
| Expense Ratio | - |
Top Fund Holdings for ADI
Filing Date: 02/29/2012| Name | Position | Value | % of Total |
|---|---|---|---|
| C 0 01/14/13 | 300 | 288,807 | 9.665% |
| M&G Optimal Income Fund | 10,620 | 163,057 | 5.457% |
| Morgan Stanley Investment Fund | 4,250 | 161,798 | 5.415% |
| REESM 4 ¾ 09/18/13 | 150 | 155,810 | 5.214% |
| SPGB 3.9 10/31/12 | 150 | 152,425 | 5.101% |
| SPGB 2 ½ 10/31/13 | 150 | 148,730 | 4.977% |
| ELESM Float 07/05/12 | 150 | 134,807 | 4.511% |
| VOD 6 ⅞ 12/04/13 | 100 | 111,513 | 3.732% |
| BBVA Bonos 2014 FI | 10,000 | 109,204 | 3.655% |
| FADE 5 06/17/15 | 100 | 104,639 | 3.502% |
Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
- 1
- 2
- 3
- 4
- 5
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page